PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange. The company is developing therapeutic products based on its proprietary photochemical internalisation (PCI) technology.   The PCI technology induces triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities, such as small molecules, ADCs and siRNA.  The company currently has a bile duct cancer program in phase I/II clinical Development.

The company is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination.  It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs (Cytotoxic T Lymphocytes) by enhancing the MHC I antigen presentation of antigen presenting cells. When applied more specifically to the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.

Please contact us, for more information.

PCI Biotech is a member of Oslo Cancer Cluster NCE. Oslo Cancer Cluster is a member organization for Norwegian and International stakeholders within cancer research and development. Oslo Cancer Cluster has members from the biotechnology industry, the government, patient organizations, research institutions and hospitals. Oslo Cancer Cluster aims to develop new cancer medication faster than today. Read more about Oslo Cancer Cluster here: